Capricorn's Axogen Bet: Big Confidence, Big Gains

Capricorn Fund Managers recently invested heavily in Axogen stock, acquiring 687,600 shares for $22.36 million, with the stake now worth $22.78 million. This is their fourth-largest holding, making Axogen a significant player in their U.S. equity portfolio. Axogen specializes in nerve repair solutions, with their Avance Nerve Graft recently approved by the FDA, potentially boosting revenue. The company is expected to report Q1 results on April 28th, which could impact their investment and investor sentiment. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/b81129dfec1f882d